ReviewCancer letters2014
Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies.
Review in Cancer letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 128 citations in OpenAlex.
- Baicalein-loaded nanocochleates for improving oral bioavailability: design, statistical optimization, and in vivo pharmacokinetic evaluation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- FuTCM-PDD: a multi-level information fusion framework integrating KAN modeling and AutoML for phenotype-based drug discovery from Traditional Chinese Medicine.Chinese medicine · 2026Article
- Baicalin: A comprehensive review of its molecular mechanisms and pharmacological activities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Targeting ferroptosis: a novel pathway in oral, oropharyngeal, hypopharyngeal, and laryngeal cancers.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Review
- Advances in the role of baicalin and baicalein in colon cancer: mechanisms and therapeutic potential.Discover oncology · 2025Review
- The Therapeutic Potential of Baicalin and Baicalein in Breast Cancer: A Systematic Review of Mechanisms and Efficacy.Current issues in molecular biology · 2025Review
- Natural products for intervertebral disc degeneration: mechanistic insights and therapeutic potentials.Frontiers in pharmacology · 2025Review
- Baicalin: a potential therapeutic agent for acute kidney injury and renal fibrosis.Frontiers in pharmacology · 2025Review
- Integrated neurobehavioral and organ-specific safety profiling of baicalin: acute/subacute toxicity studies.Frontiers in pharmacology · 2025Article
- Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment.Heliyon · 2024Review
- An Amorphous Solid Dispersion of Baicalin and its Oral Therapeutic Effect on Ulcerative Colitis.Pharmaceutical research · 2024Article
- Effect of baicalin and baicalin-bovine serum albumin nanoparticle against bendiocarb exposure in rats.Toxicology research · 2024Article
- Role of Mitochondrial Reactive Oxygen Species-Mediated Chaperone-Mediated Autophagy and Lipophagy in Baicalin and N-Acetylcysteine Mitigation of Cadmium-Induced Lipid Accumulation in Liver.Antioxidants (Basel, Switzerland) · 2024Article
- Antimicrobial Potential of Polyphenols: An Update on Alternative for Combating Antimicrobial Resistance.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- FA-PEG Modified ZIF(Mn) Nanoparticles Loaded with Baicalin for Imaging-Guided Treatment of Melanoma in Mice.International journal of nanomedicine · 2024Article
- Identification of two flavonoids antiviral inhibitors targeting 3C-like protease of porcine epidemic diarrhea virus.Frontiers in microbiology · 2024Article
- Pharmacological overview of hederagenin and its derivatives.RSC medicinal chemistry · 2023Review
- Enzymatic Synthesis of α-Glucosyl-Baicalin through Transglucosylation via Cyclodextrin Glucanotransferase in Water.Molecules (Basel, Switzerland) · 2023Article
- Baicalin-Current Trends in Detection Methods and Health-Promoting Properties.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Despite tremendous advances in the targeted therapy for various types of hematological malignancies with successful improvements in the survival rates, emerging resistance issues are startlingly high and novel therapeutic strategies are urgently needed. In addition, chemoprevention is currently becoming an elusive goal. Plant-derived natural products have garnered considerable attention in recent years due to the potential dual functions as chemotherapeutics and dietary chemoprevention. One of the particularly ubiquitous families is the polyphenolic flavonoids. Among them, baicalin and its aglycone baicalein have been widely investigated in hematological malignancies because both of them exhibit remarkable pharmacological properties. This review focuses on the recent achievements in drug discovery research associated with baicalin and baicalein for hematological malignancy therapies. The promising anticancer activities of these two flavonoids targeting diverse signaling pathways and their potential biological mechanisms in different types of hematological malignancies, as well as the combination strategy with baicalin or baicalein as chemotherapeutic adjuvants for recent therapies in these intractable diseases are discussed. Meanwhile, the biotransformation of baicalin and baicalein and the relevant approaches to improve their bioavailability are also summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.